Alison Kanski

6 days ago | precisionmedicineonline.com | Alison Kanski

NEW YORK – Researchers have developed a blood-based test for predicting whether non-Hodgkin lymphoma patients will respond to autologous CAR T-cell therapy prior to starting treatment. The researchers published results from a training and validation study of the predictive tool, called InflaMix, in Nature Medicine earlier this month.

2 weeks ago | precisionmedicineonline.com | Alison Kanski

NEW YORK – ALX Oncology has brought its second candidate therapy into the clinic, a potential first-in-class EGFR-targeted antibody-drug conjugate (ADC) that could help reduce toxicity for patients with EGFR-mutant tumors. The US Food and Drug Administration cleared the firm's investigational new drug application this week, allowing ALX to begin a Phase I trial of the drug, dubbed ALX2004, in EGFR-expressing solid tumors. ALX CEO Jason Lettmann said the firm expects to begin the trial mid-year.

3 weeks ago | precisionmedicineonline.com | Alison Kanski

NEW YORK – Results from an arm of the NCI-MATCH trial evaluating AstraZeneca's AKT inhibitor Truqap (capivasertib) in AKT1 E17K-mutated solid tumors demonstrated activity for the drug in gynecological as well as breast cancer and identified potential biomarkers of response. The cohort, called arm Y of NCI-MATCH precision medicine basket trial, enrolled 35 patients with a range of solid tumors harboring AKT1 E17K mutations.

3 weeks ago | precisionmedicineonline.com | Alison Kanski

NEW YORK – Some patients with KRAS G12C-mutant and PD-L1-high advanced non-small cell lung cancer lived for more than two years without their cancer progressing on first-line combination treatment with Bristol Myers Squibb's KRAS inhibitor Krazati (adagrasib) and Merck's checkpoint inhibitor Keytruda (pembrolizumab).

1 month ago | precisionmedicineonline.com | Alison Kanski

NEW YORK – Oncologists used Reveal Genomics' predictive assay, HER2DX, to alter neoadjuvant and adjuvant treatment plans for nearly half of their early-stage HER2-positive breast cancer patients, three quarters of whom saw a de-escalation in their treatment, a real-world study has shown. The observational study included nearly 300 patients with newly diagnosed stage I to stage III HER2-positive breast cancer treated at 12 hospitals across Spain.